- Home
- OABI vs SGHT Comparison
OABI vs SGHT Comparison
Compare OABI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- SGHT
- Stock Information
- Founded
- OABI 2012
- SGHT 2011
- Country
- OABI United States
- SGHT United States
- Employees
- OABI N/A
- SGHT N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- OABI Health Care
- SGHT Health Care
- Exchange
- OABI Nasdaq
- SGHT Nasdaq
- Market Cap
- OABI 239.0M
- SGHT 193.2M
- IPO Year
- OABI N/A
- SGHT 2021
- Fundamental
- Price
- OABI $1.58
- SGHT $7.25
- Analyst Decision
- OABI Strong Buy
- SGHT Buy
- Analyst Count
- OABI 3
- SGHT 8
- Target Price
- OABI $6.67
- SGHT $4.93
- AVG Volume (30 Days)
- OABI 544.6K
- SGHT 280.7K
- Earning Date
- OABI 11-04-2025
- SGHT 11-06-2025
- Dividend Yield
- OABI N/A
- SGHT N/A
- EPS Growth
- OABI N/A
- SGHT N/A
- EPS
- OABI N/A
- SGHT N/A
- Revenue
- OABI $21,094,000.00
- SGHT $76,052,000.00
- Revenue This Year
- OABI N/A
- SGHT N/A
- Revenue Next Year
- OABI $48.89
- SGHT $12.04
- P/E Ratio
- OABI N/A
- SGHT N/A
- Revenue Growth
- OABI 3.36
- SGHT N/A
- 52 Week Low
- OABI $1.22
- SGHT $2.03
- 52 Week High
- OABI $4.61
- SGHT $8.06
- Technical
- Relative Strength Index (RSI)
- OABI 49.87
- SGHT 79.17
- Support Level
- OABI $1.33
- SGHT $4.86
- Resistance Level
- OABI $1.64
- SGHT $8.06
- Average True Range (ATR)
- OABI 0.09
- SGHT 0.40
- MACD
- OABI 0.01
- SGHT 0.23
- Stochastic Oscillator
- OABI 55.92
- SGHT 76.92
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.